You are here

Study Investigating Enbrel Treatment for Ankylosing Spondylitis

Last updated on May 11, 2018

FOR MORE INFORMATION
Study Location
Gyunggi-do, , 463-707 Korea, Republic of
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Ankylosing Spondylitis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Adults: Severe ankylosing spondylitis (AS) in patients who do not respond adequately
to previous therapy

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Patients with known hypersensitivity to Enbrel or any component of the product

- Patients with sepsis or risk of sepsis

- Patients with active infections including chronic or localized infections such as
tuberculosis.

NCT00195416
Pfizer
Completed
Study Investigating Enbrel Treatment for Ankylosing Spondylitis

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Ankylosing Spondylitis
NCT03502616
All Genders
18+
Years
Multiple Sites
Ankylosing Spondylitis, Psoriatic Arthritis, Rheumatoid Arthritis, Ankylosing Spondylitis
NCT00273858
All Genders
18+
Years
Multiple Sites
Ankylosing Spondylitis
NCT01786668
All Genders
18+
Years
Multiple Sites
Study Investigating Enbrel Treatment for Ankylosing Spondylitis
A Drug Use Investigation of Enbrel for Post-marketing Surveillance (PMS) for Ankylosing Spondylitis

To identify the following problems and questions with respect to the safety and effectiveness of Enbrel during the post-marketing period as required by Korea Food and Drug Administration (KFDA)'s regulations.

  1. Unknown adverse reactions, especially serious adverse reactions
  2. Change of the incidences of adverse reactions under the routine drug uses
  3. Factors that may affect the safety of the drug
  4. Factors that may affect the effectiveness of the drug
Not Provided
Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Primary care clinic, secondary and tertiary medical centers
Ankylosing Spondylitis
Drug: Etanercept
Etanercept 25mg Injection, 2 times/week
Not Provided
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
526
August 2008
August 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Adults: Severe ankylosing spondylitis (AS) in patients who do not respond adequately to previous therapy

Exclusion Criteria:

  • Patients with known hypersensitivity to Enbrel or any component of the product
  • Patients with sepsis or risk of sepsis
  • Patients with active infections including chronic or localized infections such as tuberculosis.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Korea, Republic of
 
 
NCT00195416
0881A-102018
No
Not Provided
Not Provided
Wyeth (Registry Contact: Clinical Trial Registry Specialist), Wyeth
Wyeth is now a wholly owned subsidiary of Pfizer
Not Provided
Study Director: Medical Monitor Wyeth is now a wholly owned subsidiary of Pfizer
Wyeth is now a wholly owned subsidiary of Pfizer
September 2009

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now